Wondering how you did compared to the rest of your colleagues? See the results.

**QUESTION 1**

To be eligible for inclusion in the Topicort Topical Spray phase 3 studies, candidates had to have:

A. PGA Score of 3 (moderate) or 4 (severe) for overall disease severity  
B. BSA ≥ 10%  
C. Target Lesion area ≥ 5 cm²  
D. All of the above

**ANSWER**

All patients included in Topicort Spray Phase III trials had moderate to severe plaque psoriasis. The National Psoriasis Foundation defines 3-10% BSA as moderate and anything greater than 10% as severe disease. Patients with extensive psoriasis (defined as having BSA > 3%) are considered candidates for systemic therapy, including biologics. Patients in Topicort Spray clinical trials had to have at least 10% BSA to be included, but the mean BSA was actually 17%, so the patients were on the verge of the upper limit of moderate, and crossing into the severe category.

In Topicort Spray clinical trials, the investigators were asked to find the worst plaque on the body—a Target Lesion, and evaluate it on elements of scaling, erythema, and plaque thickness for a Total Lesion Severity Score of ≥ 7. The mean Target Lesion Size was 45-47 cm².

For Physician Global Assessment all patients had to be moderate/severe (~70% were moderate and ~30% severe). The Topicort® Spray Challenge tested your knowledge.

Thanks to your participation, both the National Psoriasis Foundation and the American Academy of Dermatology’s Camp Discovery received a generous donation due to your involvement.

**RESULTS:**

85% of participants answered correctly.

Topicort® Topical Spray is a topical corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.

**IMPORTANT SAFETY INFORMATION**

- Topicort® Topical Spray is a topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Please see additional Important Safety Information throughout this document. Please see enclosed full Prescribing Information.
QUESTION 2
In Topicort Spray clinical trials, how quickly were some patients able to see symptom improvement?
1 week
2 weeks
3 weeks
4 weeks

ANSWER
At the end of Week 1 on Topicort Spray treatment, 6 out of 10 patients (61%) saw at least 50% improvement in the very worst lesion on their body, as compared to 19% on the vehicle alone.¹

• 70% of patients with scaling were Mild or better at Week 1
• 51% of patients with erythema were Mild or better at Week 1
• 49% of patients with plaque elevation were Mild or better at Week 1

Patients on Topicort Spray started to see symptom relief as early as week 1 of treatment and continued to see sustained relief throughout the 4-week treatment period.

IMPORTANT SAFETY INFORMATION
• Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.

Please see additional Important Safety Information throughout this document.
Please see enclosed full Prescribing Information.
QUESTION 3
Among topical steroids, which of the following groups, based on molecular structure, is believed to have the lowest potential for allergic sensitization?
A
B
C
R2
D2

ANSWER
Structural Group C molecules have a methyl Group on C16 and no esters on C17. Allergy to Group C steroids is less common because steroid molecules in this group are less structurally related to the other groups. Topicort Spray is the only Class 1 corticosteroid in Structural Group C.

IMPORTANT SAFETY INFORMATION
• Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression.

Please see additional Important Safety Information throughout this document.
Please see enclosed full Prescribing Information.
QUESTION 4
Topicort (desoximetasone) Topical Spray, 0.25% contains the following inactive ingredients (select all that apply)?
L-Menthol  
Mineral Oil  
Isopropyl Myristate  
Glyceryl Oleate  
Isopropyl Alcohol  
Sodium Laurel Sulfate  
Propylene Glycol

ANSWER
Topicort Spray contains the following inactive ingredients.
• L-Menthol, a cooling sensation agent/enhancer
• Mineral Oil, an Oleaginous vehicle/emollient
• Isopropyl Myristate, a Penetration enhancer, co-solvent
• Glyceryl Oleate, a Skin conditioner
• Isopropyl Alcohol, a Solvent

It is important to note that none of the inactive ingredients are on the NACDG top 65 allergen list. Topicort Spray does not contain commonly known irritants such as Propylene Glycol, Parabens or Sodium Laurel Sulfate.

IMPORTANT SAFETY INFORMATION
• Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local reactions may be irreversible.

Please see additional Important Safety Information throughout this document.
Please see enclosed full Prescribing Information.
QUESTION 5
What was the reported rate of stinging and burning in Topicort Spray subjects during Phase III trials?

<1%
10-20%
30-40%
≥40%

ANSWER
No stinging, burning or atrophy was reported by Topicort Spray subjects. Furthermore, there were no serious adverse events reported in Topicort Spray Phase III trials; dryness, irritation, and pruritus occurred less frequently in the Topicort Spray group as compared to vehicle alone.¹

IMPORTANT SAFETY INFORMATION
• Safety and effectiveness of Topicort® Topical Spray in patients younger than 18 years of age have not been studied; therefore use in pediatric patients is not recommended.

Please see additional Important Safety Information throughout this document.
Please see enclosed full Prescribing Information.
QUESTION 6
When filling a Topicort prescription through TaroPharma Direct, a patient access program, eligible patients with any level of commercial insurance coverage, including high deductible, pay:

A. $0
B. $50
C. Full cost of medication

ANSWER
Topicort is available for $0 for HMO/PPO plans and high-deductible plans. TaroPharma Direct makes it easy—just 3 steps:

1. You select the pharmacy you wish to use and send the prescription.
2. The pharmacy contacts the patient and validates insurance coverage.
3. The prescription is mailed directly to the patient at their home or workplace.

Patients not only get the lowest cost available, but the prescription is delivered to their home or business within 48 hours* as well. You get the benefit of knowing your patient got the medicine you prescribed! Rely on TaroPharma Direct.

*Based on when patient information is received

IMPORTANT SAFETY INFORMATION
- Topicort® Topical Spray is a topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Please see additional Important Safety Information throughout this document.
Please see enclosed full Prescribing Information.